BSECompany Update24 Aug 2026 · 24 Aug 2026, 08:24 pm

Intimation of Investor Meet

Natco Pharma Ltd · 524816

✦ AI SummaryMgmt Change

Natco Pharma Ltd has announced an investor meet, where company officials will participate in discussions with investors. The meet will be held on various dates in August 2026, and the company's latest investor presentation is available on its website.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment6/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Attachments (1)

📄

471a5669-d584-4dd5-af9e-152f8f37c0fb.pdf

pdf

Download →
View document text
24th August 2026 Corporate Relationship Department The Manager - Listing M/s. BSE Limited M/s. National Stock Exchange of India Ltd Mumbai 400001 Bandra (E) Mumbai 400051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: Intimation of Schedule of Investors Meet Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) Pursuant to Regulation 30(6) read with Para A of Part A of Schedule III of the Listing Regulations, this is to inform you that the officials of the company will be participating in the following investor meeting: Date of Time Investor / Meeting Type of Nature of Location meeting name meeting Meeting Thursday, 9:00 AM to Investors meeting In-person Group Mumbai, 27th August 6:00 PM organised by Nuvama meeting Maharashtra 2026 Wealth Management Thursday, 9:00 AM to Limited and ICICI Hong Kong 27th August 5:00 PM on Securities Limited 2026 to 27th August Friday, 28th 2026 and August 2026 9:00 AM to 1:00 PM 28th August 2026 The latest investors’ presentation to be discussed has already been placed on the website of the Company i.e., https://admin.natcopharma.co.in/wp- content/uploads/2026/08/InvestorPresentation19082026.pdf The schedule of the above-mentioned meeting is subject to change, and the change may occur due to exigencies on the part of Investor / Company. No Unpublished Price Sensitive Information (UPSI) pertaining to the Company is intended to be discussed during the interactions. Kindly take the same on record. Thanking you, Yours faithfully, For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer